The global mammalian polyclonal IgG antibody market size reached US$ 1,038.2 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,415.3 Million by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.
Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations. Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.
Mammalian Polyclonal IgG Antibody Market Trends:
The increasing prevalence of various chronic disorders, including cancer and autoimmune ailments, and the rising need for antibodies for multiple immunoassay tests and therapeutic and analytical applications in research settings are primarily driving the market growth. In line with this, significant investments in biotechnology and pharmaceutical companies by governments to formulate effective novel vaccinations and injectables through advanced technologies are acting as another growth-inducing factor. Additionally, the ongoing innovation of creative mammalian antibodies by biopharma organizations for quality control (QC) is contributing to the market growth. Moreover, the escalating biomarkers approval and their extensive usage by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia are supporting the market growth. Apart from this, significant enhancements in the healthcare infrastructure and research and development (R&D) activities to enhance antibody efficacy are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global mammalian polyclonal IgG antibodymarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, product, application and end use.
Breakup by Type:
Breakup by Product:
Breakup by Application:
Breakup by End Use:
Academic and Research Institutes
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.
Base Year of the Analysis
Type, Product, Application, End Use, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global mammalian polyclonal IgG antibody market was valued at US$ 1,038.2 Million in 2022.
We expect the global mammalian polyclonal IgG antibody market to exhibit a CAGR of 5.2 % during 2023-2028.
The growing number of biochemical research activities, along with the elevating requirement for biomarkers by clinicians for rapid diagnosis of B-cell lymphoma and leukemia, is primarily driving the global mammalian polyclonal IgG antibody market.
The sudden outbreak of the COVID-19 pandemic has led to the rising demand for mammalian polyclonal IgG antibody by numerous biotechnology and pharmaceutical companies to formulate effective novel vaccines against the coronavirus infection.
Based on the type, the global mammalian polyclonal IgG antibody market has been divided into goat, rabbit, horse, mouse, and others, where goat currently holds the majority of the global market share.
Based on the product, the global mammalian polyclonal IgG antibody market can be segmented into cardiac markers, metabolic markers, renal markers, and others. Currently, metabolic makers exhibit a clear dominance in the market.
Based on the application, the global mammalian polyclonal IgG antibody market has been categorized into ELISA, immunoturbidimetry, immunoelectrophoresis, antibody identification, immunohistochemistry, immunocytochemistry, and western blotting. Among these, western blotting currently accounts for the largest market share.
Based on the end use, the global mammalian polyclonal IgG antibody market can be bifurcated into hospitals, diagnostic centers, and academic and research institutes. Currently, diagnostic centers exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global mammalian polyclonal IgG antibody market include Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc., and Thermo Fisher Scientific Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.